The reported survival benefit in adjuvant immunotherapy for melanoma is impressive. Cost-effectiveness analyses in different healthcare systems are needed. - https://de.itsbetter.com/search/show/1211620-hospital-abc.html , This study raises concerns about the long-term safety of prolonged PPI use. Periodic reassessment of indication is warranted. .